Position in MYGN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,019,497
+$275,076 QoQ
Shares Held
178,546
+7.9% QoQ
Ownership
0.187%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#57
of 196 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 10%
Shared 0%
None 90%
Common Shares in MYGN Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026MARTINGALE ASSET MANAGEMENT L P holds $22,258,629 across 6 Diagnostics & Research names. MYGN ranks #4 (4.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
35,160 | $17,627,817 | |
| 2 | MEDP |
Medpace Holdings, Inc.
|
2,481 | $1,313,912 | |
| 3 | DHR |
Danaher Corp /De/
|
6,172 | $1,175,642 | |
| 4 | MYGN |
Myriad Genetics Inc
This page
|
178,546 | $1,019,497 | |
| 5 | VCYT |
Veracyte, Inc.
|
14,209 | $834,494 | |
| 6 | QGEN |
Qiagen N.V.
|
7,347 | $287,267 |
All Filings in MYGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,019,497 | 178,546 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $744,421 | 165,427 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $792,796 | 128,910 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $535,193 | 74,024 | Shares | Sole | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||